Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04435691 · ClinicalTrials.gov registry record · Phase 1
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT04435691: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT04435691 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04435691, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies the side effects and best dose of magrolimab and venetoclax when given together with azacitidine and to see how well they work in treating patients with acute myeloid leukemia. Magrolimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving magrolimab, azacitidine, and venetoclax may help to control the disease.
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- BIOLOGICAL Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2025-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04435691
The ClinicalTrials.gov registry entry for NCT04435691 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT04435691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04435691 about?
NCT04435691 is a clinical study titled "Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia". This phase Ib/II trial studies the side effects and best dose of magrolimab and venetoclax when given together with azacitidine and to see how well they work in treating patients with acute myeloid leukemia. Magrolimab is a monoclonal antibody that may interfere with the ability of cancer cells to g...
What is the current status of trial NCT04435691?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2020-07-28. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT04435691?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Magrolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04435691?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.